February 25, 2022, Rancho launched Single Cell Data Science Consortium with 4 Charter Members. This multi-year effort will deliver harmonized single cell experiments more quickly and cost effectively.
Due to their enormous potential for advancing drug discovery, there continues to be an exponential growth in the use of single cell sequencing methods, with pharmaceutical companies continuing to invest in them. In addition, there is an ever-increasing amount of single cell datasets being generated and deposited in the public domain.
The availability of vast amounts of publicly available single cell datasets offers pharmaceutical companies the opportunity to expand the universe of experiments available to their scientists many fold. While many of these datasets are freely available, they come with hidden costs that hinder the ability of companies to exploit them to their maximum potential:
Algorithms for analysis of single cell data to help extract valuable information for drug discovery are also being published more frequently. However, it is challenging for pharmaceutical companies to:
Funded by pharmaceutical companies with common goals and needs in single cell data, a pre-competitive approach will help to deliver:
Single Cell Data Science Consortium (SCDS)
Benefits of Membership
Membership in the Single Cell Data Science Consortium